Refresh highlights menopause care after FDA estradiol patch update

Refresh - Aesthetics & Wellness is urging Florida women to treat menopause care as an individualized medical decision after the FDA said some patients are having trouble accessing estradiol patches because of higher demand. The guidance comes as federal label changes and rising interest in hormone therapy are reshaping how patients and clinicians discuss treatment.

Why it matters: - Florida women using or considering hormone therapy may face patch availability issues and more complex treatment choices. - The FDA update underscores a broader shift toward individualized menopause care, not a one-size-fits-all approach. - Patients currently on prescription hormone therapy should speak with their prescribing provider before changing or stopping medication.

What happened: - Refresh - Aesthetics & Wellness released guidance after a Sept. 3, 2026 FDA update on estradiol transdermal patches. - The FDA said some patients have had trouble getting their usual estradiol patches because demand has increased. - The agency said it is working with all six manufacturers to increase supply. - Refresh said the issue is part of a wider national conversation about menopause treatment and hormone replacement therapy, also called menopausal hormone therapy.

The details: - The FDA said estradiol transdermal patches remain available, but access to specific brands or products can vary by pharmacy and location. - The agency said the supply of FDA-approved estradiol transdermal patches has nearly doubled over the past year. - Manufacturers are increasing production, adding manufacturing shifts, expanding capacity and adding specialized equipment. - Women who cannot find their usual patch should not stop treatment, change doses or substitute products on their own. - The FDA recommends calling a pharmacist about availability and contacting the prescribing healthcare provider about alternatives if needed. - In February 2026, the FDA approved labeling changes for six menopausal hormone therapy products. - Those changes removed boxed-warning statements about cardiovascular disease, breast cancer and probable dementia. - The labeling change did not make hormone therapy risk-free or appropriate for every patient. - The American College of Obstetricians and Gynecologists says hormone therapy can help relieve menopause and perimenopause symptoms such as hot flashes and night sweats. - The ACOG says suitability depends on symptoms, personal medical history and family medical history. - Certain medical conditions may make systemic hormone therapy inappropriate, and different formulations and routes of administration can carry different considerations. - Estrogen can be delivered systemically through patches, pills, gels and sprays. - A clinician may also determine that a progestogen is appropriate when the uterus is present. - Nonhormonal treatment options also exist for some menopause symptoms. - Refresh says menopause symptoms such as hot flashes, night sweats, vaginal dryness and sleep disruption can overlap with other health concerns. - Refresh provides menopause and hormone replacement therapy evaluations at nine Florida locations: Jupiter, Wellington, Port St. Lucie, Vero Beach, Fort Lauderdale, Tampa, St. Petersburg, Brandon and Palm Harbor. - The company’s menopause and hormone programs include a medical evaluation, symptom and health-history review, clinically appropriate diagnostic testing, and ongoing follow-up and monitoring. - Refresh says laboratory testing can help guide care, but menopause treatment should not be based on a single hormone level or lab result. - The company says age, menstrual history, medications, medical history and risk factors can all affect treatment decisions. - When hormone therapy is being considered, Refresh providers assess whether treatment is appropriate and discuss expectations, benefits, risks and monitoring. - Refresh’s website for more information is more information.

Between the lines: - The push is as much about education as treatment access. - Refresh is positioning menopause care as a clinical conversation shaped by symptoms and medical history, not social-media trends or blanket protocols. - The FDA’s patch supply update may add urgency for patients, but it also reinforces the need for pharmacy checks and prescriber guidance before making changes.

What's next: - The FDA is expected to keep working with manufacturers to improve estradiol patch supply. - Patients who cannot get their usual product may need alternative formulations or dosing plans from their clinician. - Refresh is encouraging women with perimenopause or menopause symptoms to discuss their options with a qualified healthcare provider. - More women are likely to seek information about hormone therapy as federal guidance and public attention continue to evolve.

The bottom line: - Estradiol patch access is improving, but menopause treatment still depends on individualized medical review and shared decision-making.